Profitability
Weight: 20%
D-
30
- 5yr Avg ROIC -10.6%
- Operating Margin Trend +12059.71 pp/yr
CRSP
CRISPR Therapeutics AG
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
8
- 5yr Avg ROE -14.3%
- 5yr Share-Count CAGR 2.8%
Growth Quality
Weight: 15%
F
15
- 5yr Revenue CAGR -75.1%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 15%
D+
43
- 5yr FCF Margin -26504.6%
- 5yr FCF/NI Conversion 1.21x
Balance Sheet
Weight: 20%
C-
44
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 2.49
Stability
Weight: 15%
B-
65
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 3
- Negative-Revenue Years (5) 3/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 2 gurus held; 1 added.
- Holders
- 2
- Avg Δ position
- +186.3%
- New buys
- 0
- Full exits
- 0
- Cooperman increased +373%